PepSavvySearch peptides

Search peptides

Popular peptides
↑ ↓ Navigate ↵ OpenBrowse all peptides
Saved0
All peptidesSelank
Mind & sleep

Selank

Tuftsin analog

No FDA-approved Selank product identified; research formulations are not approved anxiety treatments.

What does it do?

Anxiety

Study

Small human studies compared Selank with benzodiazepines.1

Stress and calm-focus

Community

Described in community summaries; predictable individual benefit is unproven.6

Molecular information

3

Amino-acid sequence

  1. Thr
  2. Lys
  3. Pro
  4. Arg
  5. Pro
  6. Gly
  7. Pro

7 residues · N → C3

Length7 amino acids
Molecular weight · Da751.9 Da
Molecular formulaC33H57N11O93

Free-acid parent peptide. Acetate counterions and N-acetyl derivatives must be distinguished.

Pharmacokinetics

Unverified reference estimateNot independently confirmed
Reference half-life3 min12
Route / formulationSource page: Injectable. Exact PK route not verified.

This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.

Illustrative half-life model for Selank: Pep-Pedia estimateNormalized terminal-phase decline, not measured blood concentration or effect duration. Five half-lives leaves 3.125%. 0%50%100%03 min6 min9 min12 min15 min1 half-life
50%of reference level

Illustrative scenario using an unverified reference estimate.

About 3% remaining after 15 min

Five half-lives in this estimated model. This is not a prediction of when effects stop.

About this estimate

Population: Not established by the reference estimate

Source’s stated attribution: Russian pharmaceutical data

Source’s reported peak time: 20 min. This has not been independently confirmed and is not used in the elimination curve.

100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Anxiety signal with limited reporting

The 62-patient comparison described anxiety improvement similar to medazepam and additional anti-fatigue effects; the abstract gives no numerical effect size.1

Reported timelines

Reference & community

Source expectations

Injection calm 30–60 min, clarity 1–3 days, resilience 1 week, cognitive peak 1–2 weeks.13

Nasal

15–30 min onset, 4–6 h claimed duration; route comparisons unverified.13

These are reported timelines, not a prediction of your response.

Doses & schedules

13 rows
Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
RouteDoseFrequencyGoal / evidenceDurationReferences
UnspecifiedNot specifiedNot specifiedAnxiety and neurasthenia symptoms62 patients: Selank 30, medazepam 32Human studyNot specified1
SubQ250 mcg dailyOnce dailyMild anxiety reliefReference report2-8 weeks, break not required but recommended13
SubQ250 mcg twice dailyMorning and eveningModerate anxiety/cognitive enhancementReference report2-8 weeks, break not required but recommended13
SubQ500 mcg dailyDivided dosesIntensive anxiety/stress managementReference report2-8 weeks, break not required but recommended13
SubQ250-350 mcg dailyMorning onlyCognitive enhancement/nootropic useReference report2-8 weeks, break not required but recommended13
SubQ250 mcg twice dailyConsistent timingPTSD/trauma supportReference report2-8 weeks, break not required but recommended13
SubQ250 mcg dailyOnce daily for 2-4 weeksImmune support during stressReference report2-8 weeks, break not required but recommended13
IntranasalNasal300 mcg (1 spray)Once dailyMild anxiety/cognitive enhancementReference report2-8 weeks continuous or as-needed use13
IntranasalNasal600 mcg (2 sprays or 1 per nostril)Once dailyModerate anxiety reliefReference report2-8 weeks continuous or as-needed use13
IntranasalNasal900 mcg (3 sprays)Once daily or dividedIntensive anxiety/GAD treatmentReference report2-8 weeks continuous or as-needed use13
IntranasalNasal300-600 mcgAs needed (max 3x daily)As-needed anxiety reliefReference report2-8 weeks continuous or as-needed use13
IntranasalNasal300 mcg30-60 min before cognitive demandsCognitive enhancement before tasksReference report2-8 weeks continuous or as-needed use13
IntranasalNasal300-600 mcgDuring acute episodesPTSD/trauma episode managementReference report2-8 weeks continuous or as-needed use13

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports13

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period
2-8 weeks, break not required but recommended
Break
1-2 weeks between cycles (optional)
Reported timing

Morning for cognitive benefits, evening for anxiety

Nasal

Use period
2-8 weeks continuous or as-needed use
Break
1-2 weeks between cycles (optional)
Reported timing

Morning for cognitive benefits, as-needed for anxiety

Side effects & safety

Limited human safety characterization

FDA states that important human safety information for Selank acetate is lacking.

2

Immune-reaction concern

FDA flags aggregation and peptide impurities as possible immunogenicity risks for some routes.

2

Formulation gap

Small clinical studies do not establish the long-term safety of injectable research-vial Selank.

12

Additional reported cautions

Reference reports13

Reported problems

Local/nasal irritation, headache, nausea and unexpected fatigue or mood effects.

Stop symptoms

Allergy, infection/discharge, persistent bleeding/burning, neurological symptoms or worsening anxiety.

Uncertainty

Claims of no dependence, sedation or tolerance are not universal guarantees.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

10 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Benzodiazepines

Caution reported

Additive sedation possible.13

Reference report · Pep-Pedia label: Use Caution

SSRIs

Caution reported

Psychiatric interactions uncertain.13

Reference report · Evidence context: Monitor combination

Alcohol

Avoidance reported

Sedation/unpredictable effects.13

Reference report · Pep-Pedia label: Avoid Combination

Semax

Unverified pairing

Unproven nootropic stack.13

Reference report · Pep-Pedia label: Synergistic

BPC-157

Unverified pairing

Untested pairing.13

Reference report · Pep-Pedia label: Compatible

Noopept

Unverified pairing

Untested pairing.13

Reference report · Pep-Pedia label: Compatible

Phenylpiracetam

Unverified pairing

Untested pairing.13

Reference report · Pep-Pedia label: Compatible

Modafinil

Unverified pairing

Untested pairing.13

Reference report · Pep-Pedia label: Compatible

Phenazepam

Human study

A 70-patient comparative study reported fewer phenazepam adverse effects when Selank was added. It does not establish safety with all benzodiazepines or with research-vial injections.4

Research context

Olanzapine

Theoretical

A cell experiment found altered gene-expression responses with combined exposure. This is not a demonstrated clinical interaction or evidence of safe combination use.5

Research context

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

mg

Total labeled amount of Selank.

mL

Usable capacity of the destination vial or pen cartridge.

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents Selank

Listed amounts are packaging examples. Check your actual label.

Reconstitution

No validated human preparation verified

No formulation-specific human reconstitution instructions were verified for this research powder.1

Diluent and storage

A compatible solvent, concentration, preservative and beyond-use period cannot be inferred from vial mass. The cited source does not validate a universal bacteriostatic-water recipe.1

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

The injectable steps name BAC water and refrigerated storage.

Solvents mentioned
Bacteriostatic water
Reported parameters
The injection steps state 30 days; the generic nasal banner states 28 days for BAC preparations.

The source describes gentle mixing and avoiding vigorous shaking.

The source mixes route-specific storage claims; a product-specific expiry is not established.

Nasal

Pep-Pedia distinguishes preservative-free saline from BAC water for nasal preparations.

Solvents mentioned
Sterile saline / Bacteriostatic water — source alternative
Reported parameters
Source-reported intervals: saline, 24–48 hours; BAC water, 28 days; both refrigerated. · It warns that benzyl alcohol in BAC water may irritate nasal tissue.

The source also suggests frozen aliquots; it does not establish validated stability or container compatibility for every nasal formulation.

13

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite to off-white powderReported appearanceClear reconstituted solutionReported appearanceProper labeling and batch informationReported appearanceAppropriate packaging and storageReported concernYellowing, clumping, or moisture exposureReported concernPersistent cloudiness after reconstitutionReported variationUnusual smell or burning sensation
13

Vial sizes

5mg7
10mg7

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Nasal

Unverified report13
Source-reported intervals: saline, 24–48 hours; BAC water, 28 days; both refrigerated.

Storage notes

13
Injectable

Refrigerate 2-8°C, protect from light and heat

Nasal

Refrigerate 2-8°C, good for 30 days once opened

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗
V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment
1 unit
Cartridge capacity
3 mL
Maximum setting
60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units
0.10 mL
30-unit capacity
0.30 mL
50 / 100-unit capacity
0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL
10 µL
0.10 mL
100 µL
Amount
mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device referencesAVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Evidence limits

View findings →

Robust placebo-controlled effect sizes, long-term safety, and drug interactions.1

5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Research findings

Limited human data

Source context

Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence.

Compound identity & other names

Selank is a synthetic tuftsin analog investigated for anxiety. A small comparative human study suggests a signal, but this is not enough to establish broad psychiatric benefit or the safety of self-prepared injections.

Other names: TP-7 · Selanc · tuftsin analog

No FDA-approved Selank product identified; research formulations are not approved anxiety treatments.

Selank: Thr-Lys-Pro-Arg-Pro-Gly-Pro; tuftsin-related heptapeptide.3

Pep-Pedia identity record

7 amino acids · 751.89 Da

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Reference description; checked chemical identity takes precedence when available.13

How it may work

Investigated effects involve GABA, monoamines, enkephalins, neurotrophic signaling and cytokines.13

Similar anxiety scores to an active comparator in a small study

A 2008 study assigned 30 patients to Selank and 32 to medazepam for generalized anxiety disorder or neurasthenia. It reported similar anxiolytic effects, plus antiasthenic/psychostimulant effects with Selank. The abstract gives no numerical effect size or placebo comparison.

1

Research areas and evidence gaps

Anxiety research. Small human studies compared Selank with benzodiazepines.1

  • Robust placebo-controlled effect sizes, long-term safety, and drug interactions.
  • A clinically validated subcutaneous dosing schedule; inspected human material concerned intranasal administration.
  • Whether modified Selank analogs share the parent compound's effects.

Additional uses listed by Pep-Pedia

Anxiety. Generalized/social anxiety, PTSD, stress and sleep-related claims.13

Cognition. Memory, learning, focus, neuroprotection and nasal NMDA-related claims.13

Immune. Cytokine, antiviral and inflammatory research.13

Community reports Unvalidated

PepPedia discusses anxiety relief and cognitive clarity and describes both nasal and injectable use.6

PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations. These injection schedules were not established by the inspected human trial abstract.

Search coverage and review status

No newer controlled clinical trial was verified. Added the checked Selank/olanzapine cell experiment with clinical interaction uncertainty.

Checked
2026-10-12
Search
"selank" 2025 2026 study; Selank GABAergic 2017
Catalog
Pep-Pedia ↗ · 4 listed references retained
  • Targeted search and selected primary-source checks, not an exhaustive systematic review.
  • Preserved bibliography entries marked unreviewed have not had their findings independently verified.

AI-prepared summaries. Independent medical editorial review is pending.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Primary goal

Cognitive enhancement60%
General wellness14%
Other: Anxiety3%
Other: Anxiety 3%
Recovery/Healing3%

The source hides 20 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “1604 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

  • Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
  • The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
  • Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
  • Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
  • This is a dated snapshot, not a live survey or current recommendation.
Checked 2026-10-12Poll source ↗

References

Original sources and review status. Open a reference to read its summary.

13 sources

1Selank for generalized anxiety disorder and neurastheniaTrial · 2008 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

A 62-patient active-comparator study reported similar anxiolysis to medazepam. The English abstract lacks numerical effect sizes and detailed dosing.

Similar anxiety scores to an active comparator in a small study

A 2008 study assigned 30 patients to Selank and 32 to medazepam for generalized anxiety disorder or neurasthenia. It reported similar anxiolytic effects, plus antiasthenic/psychostimulant effects with Selank. The abstract gives no numerical effect size or placebo comparison.

Original source
2FDA: compounding safety concernsRegulator · 2026 · fda.govPrimary source checked
AI-PREPARED SUMMARY

Regulatory safety assessment.

Original source
3PubChem: Selank, CID 11765600Registry · 2026 · pubchem.ncbi.nlm.nih.govPrimary source checked
AI-PREPARED SUMMARY

Chemical identity of the seven-residue free-acid peptide, formula C33H57N11O9, molecular weight 751.9 g/mol.

Original source
4Medvedev et al.: Selank added to phenazepam in anxiety disordersTrial · 2015 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

Compared phenazepam alone in 30 patients with phenazepam plus Selank in 40; reported earlier symptom change and fewer benzodiazepine adverse effects. Abstract omits dosing details.

Original source
5GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 CellsPreclinical · 2017 · doi.orgPrimary source checked
AI-PREPARED SUMMARY

Selank alone did not alter measured transcripts in IMR-32 cells; co-treatment changed responses to GABA or olanzapine. Clinical interaction consequences were not tested.

Additional research · Checked 2026-10-12

Original source
6PepPedia: reported practices (accessed October 12, 2026)Community · 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Secondary editorial account of discussed practices; not a clinical trial or representative survey.

Original source
7Research catalog: labeled quantitiesCatalog · 2026 · apexlab.orgCatalog checked
AI-PREPARED SUMMARY

Lists 5 mg and 10 mg configurations. Quantity examples only; vendor quality and suitability are not endorsed.

Original source
8GABAergic Neurotransmission Gene Expression (2016)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Rat neurotransmission-related gene expression changed after Selank; gene effects do not establish freedom from benzodiazepine-like risks in people.

Reported population / model
Rat frontal cortex

Reported study details
300 μg/kg · Real-time PCR analysis

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
9BDNF Expression Enhancement Study (2010)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The source reports approximately 30% higher hippocampal BDNF in rats; clinical memory benefit does not follow directly.

Reported population / model
Rat hippocampus

Reported study details
250-500 μg/kg · 24-hour measurement

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
10Generalized Anxiety Disorder Clinical Trial (2008)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The source describes anxiolysis in GAD/neurasthenia; duration and absence-of-dependence claims require the primary trial's methods and follow-up.

Reported population / model
Human subjects

Reported study details
GAD and neurasthenia · Multi-week treatment

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
11Memory Consolidation Enhancement (2007)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Rats with poorer initial learning reportedly improved after Selank; this is not a human memory-enhancement trial.

Reported population / model
Rat models

Reported study details
Learning paradigms · Head-to-head with Piracetam

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
12Pep-Pedia: Selank — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Lists a half-life of 3 min and a peak time of 20 min. Stated attribution: Russian pharmaceutical data. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source
13Pep-Pedia: Selank — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source
Source details

Related profiles

DSIP ↗Semax ↗